Intervacc: Encouraging Strangvac data, but US remains the focus - Redeye

Intervacc: Encouraging Strangvac data, but US remains the focus - Redeye

Intervacc has reported pharmacovigilance data from the first 100,000 doses of Strangvac sold in Europe, showing very few confirmed infections among vaccinated horses. We find the data encouraging, although it does not change our view of the near-term outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/1190631/intervacc-encouraging-strangvac-data-but-us-remains-the-focus?utm_source=finwire&utm_medium=RSS